The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

M O Leach, K M Brindle, J L Evelhoch, J R Griffiths, M R Horsman, A Jackson, G C Jayson, I R Judson, M V Knopp, R J Maxwell, D McIntyre, A R Padhani, P Price, R Rathbone, G J Rustin, P S Tofts, G M Tozer, W Vennart, J C Waterton, S R Williams, P Workman, Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee, Drug Development Office, Cancer Research UK, M O Leach, K M Brindle, J L Evelhoch, J R Griffiths, M R Horsman, A Jackson, G C Jayson, I R Judson, M V Knopp, R J Maxwell, D McIntyre, A R Padhani, P Price, R Rathbone, G J Rustin, P S Tofts, G M Tozer, W Vennart, J C Waterton, S R Williams, P Workman, Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee, Drug Development Office, Cancer Research UK

Abstract

Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used.

Figures

Figure 1
Figure 1
Example of Ktrans maps, superimposed on T1-weighted images of a patient with primary peritoneal carcinoma with left pelvic side wall nodal metastases (arrow). Images are before and 4 h after the first dose of Combretastatin (52 mg m−2). The colour scale ranges from Ktrans values of 0 to 1 min−1. A dramatic reduction of transfer constant is seen. This was published with kind permission from the Journal of Magnetic Resonance Imaging (Padhani, 2002).

References

    1. Alessi P, Ebbinghaus C, Neri D (2004) Molecular targeting of angiogenesis. Biochim Biophys Acta 1654: 39–49
    1. Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, Harsh GR, Cosgrove GR, Halpern EF, Hochberg FH (1994) Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 191: 41–51
    1. Barbier EL, den Boer JA, Peters AR, Rozeboom AR, Sau J, Bonmartin A (1999) A model of the dual effect of gadopentetate dimeglumine on dynamic brain MR images. J Magn Reson Imaging 10: 242–253
    1. Bhujwalla ZM, Artemov D, Natarajan K, Ackerstaff E, Solaiyappan M (2001) Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia 3: 143–153
    1. Bicknell R, Harris AL (1996) Mechanisms and therapeutic implications of angiogenesis. Curr Opin Oncol 8: 60–65
    1. Brasch R, Turetschek K (2000) MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol 34: 148–155
    1. Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ (1991) Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 15: 621–628
    1. Brookes JA, Redpath TW, Gilbert FJ, Needham G, Murray AD (1996) Measurement of spin-lattice relaxation times with FLASH for dynamic MRI of the breast. Br J Radiol 69: 206–214
    1. Brown J, Buckley D, Coulthard A, Dixon AK, Dixon JM, Easton DF, Eeles RA, Evans DG, Gilbert FG, Graves M, Hayes C, Jenkins JP, Jones AP, Keevil SF, Leach MO, Liney GP, Moss SM, Padhani AR, Parker GJ, Pointon LJ, Ponder BA, Redpath TW, Sloane JP, Turnbull LW, Walker LG, Warren RM (2000) Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. Magn Reson Imaging 18: 765–776
    1. Buckley DL, Kerslake RW, Blackband SJ, Horsman A (1994) Quantitative analysis of multi-slice Gd-DTPA enhanced dynamic MR images using an automated simplex minimization procedure. Magn Reson Med 32: 646–651
    1. Cao Y (2004) Antiangiogenic cancer therapy. Semin Cancer Biol 14: 139–145
    1. Choyke PL, Knopp MV, Libutti SK (2002) Special techniques for imaging blood flow to tumors. Cancer J 8: 109–118
    1. Collins DJ, Padhani AR (2004) Dynamic magnetic resonance imaging of tumour perfusion. IEEE Eng Med Biol Mag 23: 65–83
    1. d'Arcy JA, Collins DJ, Rowland IJ, Padhani AR, Leach MO (2002) Applications of sliding window reconstruction with cartesian sampling for dynamic contrast enhanced MRI. NMR Biomed 15: 174–183
    1. Evelhoch JL (1999) Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10: 254–259
    1. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, Rustin GJ (2003) Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21: 2831–2842
    1. Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, Padhani AR (2002) Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20: 3826–3840
    1. George ML, Dzik-Jurasz AS, Padhani AR, Brown G, Tait DM, Eccles SA, Swift RI (2001) Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg 88: 1628–1636
    1. Gowland PA, Stevenson PL (2003) T1: the longitudinal relaxation time. In Quantitative MRI of the Brain: Measuring Change Caused by Disease, Tofts PS (ed) pp 111–141. Chichester: John Wiley
    1. Gribbestad IS, Nilsen G, Fjosne HE, Kvinnsland S, Haugen OA, Rinck PA (1994) Comparative signal intensity measurements in dynamic gadolinium-enhanced MR mammography. J Magn Reson Imaging 4: 477–480
    1. Hacklander T, Reichenbach JR, Hofer M, Modder U (1996) Measurement of cerebral blood volume via the relaxing effect of low-dose gadopentetate dimeglumine during bolus transit. AJNR Am J Neuroradiol 17: 821–830
    1. Hacklander T, Reichenbach JR, Modder U (1997) Comparison of cerebral blood volume measurements using the T1 and T2* methods in normal human brains and brain tumors. J Comput Assist Tomogr 21: 857–866
    1. Hayes C, Padhani AR, Leach MO (2002) Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 15: 154–163
    1. He ZQ, Evelhoch JL (1998) Analysis of dynamic contrast enhanced MRI in tumours: relationship of derived parameters with physiological factors. Proceedings of the 6th Annual Meeting of the International Society of Magnetic Resonance, Sydney, 1652 Berkeley, CA: ISMRM
    1. Hennig J, Speck O, Koch MA, Weiller C (2003) Functional magnetic resonance imaging: a review of methodological aspects and clinical applications. J Magn Reson Imaging 18: 1–15
    1. Hoffmann U, Brix G, Knopp MV, Hess T, Lorenz WJ (1995) Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med 33: 506–514
    1. Howe FA, Robinson SP, McIntyre DJ, Stubbs M, Griffiths JR (2001) Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 14: 497–506
    1. ICH (1996) International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 1 May 1996.
    1. Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton L, Wagstaff J, Hakannson L, Groenewegen G, Bailey J, Smith N, Hastings D, Lawrance J, Haroon H, Ward T, McGown AT, Tang M, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H (2002) Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94: 1484–1493
    1. Johnson G, Wetzel SG, Cha S, Babb J, Tofts PS (2004) Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. Magn Reson Med 51: 961–968
    1. Kohn EC, Lu Y, Wang H, Yu Q, Yu S, Hall H, Smith DL, Meric-Bernstam F, Hortobagyi GN, Mills GB (2004) Molecular therapeutics: promise and challenges. Semin Oncol 31: 39–53
    1. Larcombe-McDouall JB, Mattiello J, McCoy CL, Simpson NE, Seyedsadr M, Evelhoch JL (1991) Size dependence of regional blood flow in murine tumours using deuterium magnetic resonance imaging. Int J Radiat Biol 60: 109–113
    1. Larsson HB, Stubgaard M, Frederiksen JL, Jensen M, Henriksen O, Paulson OB (1990) Quantitation of blood–brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med 16: 117–131
    1. Leach MO (2001) Application of magnetic resonance imaging to angiogenesis in breast cancer. Breast Cancer Res 3: 22–27
    1. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson G, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin G, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P (2003) Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol 76(Suppl 1): S87–S91
    1. Li KL, Zhu XP, Waterton J, Jackson A (2000) Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors. J Magn Reson Imaging 12: 347–357
    1. Li WW (2000) Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging. Acad Radiol 7: 800–811
    1. Liney GP, Gibbs P, Hayes C, Leach MO, Turnbull LW (1999) Dynamic contrast-enhanced MRI in the differentiation of breast tumors: user-defined versus semi-automated region-of-interest analysis. J Magn Reson Imaging 10: 945–949
    1. Ludemann L, Grieger W, Wurm R, Budzisch M, Hamm B, Zimmer C (2001) Comparison of dynamic contrast-enhanced MRI with WHO tumor grading for gliomas. Eur Radiol 11: 1231–1241
    1. Mayr NA, Yuh WT, Arnholt JC, Ehrhardt JC, Sorosky JI, Magnotta VA, Berbaum KS, Zhen W, Paulino AC, Oberley LW, Sood AK, Buatti JM (2000) Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging 12: 1027–1033
    1. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marme D, Steward WP (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21: 3955–3964
    1. Neeman M, Dafni H (2003) Structural, functional, and molecular MR imaging of the microvasculature. Annu Rev Biomed Eng 5: 29–56
    1. Newell DR, Searle KM, Westwood NB, Burtles SS (2003) Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. Br J Cancer 89: 437–454
    1. NIH Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89–95
    1. Padhani AR (2002) Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 16: 407–422
    1. Padhani AR, Husband JE (2001) Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 56: 607–620
    1. Padhani AR, MacVicar AD, Gapinski CJ, Dearnaley DP, Parker GJ, Suckling J, Leach MO, Husband JE (2001) Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging. Radiology 218: 365–374
    1. Parker GJ, Barker GJ, Tofts PS (2001) Accurate multislice gradient echo T(1) measurement in the presence of non-ideal RF pulse shape and RF field nonuniformity. Magn Reson Med 45: 838–845
    1. Parker GJ, Baustert I, Tanner SF, Leach MO (2000) Improving image quality and T(1) measurements using saturation recovery turboFLASH with an approximate K-space normalisation filter. Magn Reson Imaging 18: 157–167
    1. Parker GJ, Suckling J, Tanner SF, Padhani AR, Husband JE, Leach MO (1998) MRIW: parametric analysis software for contrast-enhanced dynamic MR imaging in cancer. Radiographics 18: 497–506
    1. Parker GJ, Suckling J, Tanner SF, Padhani AR, Revell PB, Husband JE, Leach MO (1997) Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 7: 564–574
    1. Parker GJM, Padhani AR (2003) T1w DCEMRI: T1-weighted dynamic contrast enhanced MRI. In Quantitative MRI of the Brain: Measuring Change Caused by Disease, Tofts PS (ed) pp 341–364. Chichester: John Wiley
    1. Parkes LM, Detre JA (2003) ASL: blood perfusion measurements using arterial spin labelling. In Quantitative MRI of the Brain: Measuring Change Caused by Disease, Tofts PS (ed) pp 455–473. Chichester: John Wiley
    1. Roberts HC, Roberts TP, Brasch RC, Dillon WP (2000) Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 21: 891–899
    1. Schneider G, Uder M (2003) Contrast-enhanced magnetic resonance body imaging 5. Top Magn Reson Imaging 14: 403–425
    1. Siemann DW, Chaplin DJ, Horsman MR (2004) Vascular-targeting therapies for treatment of malignant disease. Cancer 100: 2491–2499
    1. Sorensen AG, Tievsky AL, Ostergaard L, Weisskoff RM, Rosen BR (1997) Contrast agents in functional MR imaging. J Magn Reson Imaging 7: 47–55
    1. Strecker R, Scheffler K, Buchert M, Mross K, Drevs J, Hennig J (2003) DCE-MRI in clinical trials: data acquisition techniques and analysis methods. Int J Clin Pharmacol Ther 41: 603–605
    1. Taylor JS, Tofts PS, Port R, Evelhoch JL, Knopp M, Reddick WE, Runge VM, Mayr N (1999) MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging 10: 903–907
    1. Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10: 415–427
    1. Tofts PS (1997) Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7: 91–101
    1. Tofts PS, Berkowitz B, Schnall MD (1995) Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 33: 564–568
    1. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging 10: 223–232
    1. Tofts PS, Davies GR, Dehmeshki J (2003a) Histograms: measuring subtle diffuse disease. In Quantitative MRI of the Brain: Measuring Change Caused by Disease, Tofts PS (ed) pp 581–610. Chichester: John Wiley
    1. Tofts PS, Steens SCF, van Buchem MA (2003b) MT: magnetization transfer. In Quantitative MRI of the Brain: Measuring Change Caused by Disease, Tofts PS (ed) pp 257–298. Chichester: John Wiley
    1. Turetschek K, Preda A, Novikov V, Brasch RC, Weinmann HJ, Wunderbaldinger P, Roberts TP (2004) Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging 20: 138–144
    1. Verheul HM, Pinedo HM (2003) Vascular endothelial growth factor and its inhibitors. Drugs Today (Barc) 39(Suppl C): 81–93
    1. Weinmann HJ, Laniado M, Mutzel W (1984) Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 16: 167–172
    1. Wheeler-Kingshott CAM, Barker GJ, Steens SCF, van Buchem MA (2003) D: the diffusion of water. In Quantitative MRI of the Brain: Measuring Change Caused by Disease, Tofts PS (ed) pp 203–256. John Wiley: Chichester
    1. Workman P (2002) Challenges of PK/PD measurements in modern drug development. Eur J Cancer 38: 2189–2193
    1. Workman P (2003) How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 9: 891–902
    1. Workman P, Kaye SB (2002) Translating basic cancer research into new cancer therapeutics. Trends Mol Med 8: S1–S9
    1. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434
    1. Zhu XP, Li KL, Kamaly-Asl ID, Checkley DR, Tessier JJ, Waterton JC, Jackson A (2000) Quantification of endothelial permeability, leakage space, and blood volume in brain tumors using combined T1 and T2* contrast-enhanced dynamic MR imaging. J Magn Reson Imaging 11: 575–585

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever